Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial.

Authors

null

Chung-Han Lee

Memorial Sloan Kettering Cancer Center, New York, NY

Chung-Han Lee , Maria Isabel Carlo , Ying-Bei Chen , Eduard Reznik , Andrea Knezevic , Robert A Lefkowitz , Natalie Shapnik , Diana Tassone , Chloe Dadoun , Neil J. Shah , Colette Ngozi Owens , Deaglan Joseph McHugh , David Henry Aggen , Andrew Leonard Laccetti , Ritesh Kotecha , Darren R. Feldman , Robert J. Motzer , Martin H Voss

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT03635892

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4509)

DOI

10.1200/JCO.2021.39.15_suppl.4509

Abstract #

4509

Abstract Disclosures

Similar Posters

First Author: Chung-Han Lee

Poster

2023 ASCO Genitourinary Cancers Symposium

A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.

A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.

First Author: Jianbo Wang

First Author: Claudia A.M. Fulgenzi